Altis Biosystems key facts
as of Oct 2026- Developer of a stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research.
- Altis Biosystems is valued at approximately $20.0M as of Oct 2026, set at its later-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $8.8M across 3 recorded rounds; the latest was Seed Round ($2.1M) in Mar 2025.
- Notable investors include National Institutes of Health, Alexandria Venture Investments, Triangle Tweener Fund, Hatteras Venture Partners, NC Idea — 22 tracked in total.
- Altis Biosystems has filed 4 Form Ds with the SEC since 2020, most recently Apr 2025 ($2.1M sold to 9 investors).
- Status: Privately Held (backing).
Valued at $20.0M at its later-stage round, Apr 2025. Nothing has traded since.
- ·The complete investor list: 22 names
- ·Watch Altis Biosystems: the Monday email on marks, rounds and moves
Altis Biosystems funding rounds
3 roundsWho backs Altis Biosystems
22+Altis Biosystems valuation
Altis Biosystems was valued at $20 million at its later-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Altis Biosystems raised?
Altis Biosystems has raised $8.8 million across 3 recorded rounds since 2019. The largest was a $3.1 million seed round in Dec 2019; the most recent was a $2.1 million seed round in Mar 2025.
Altis Biosystems has filed 4 Form Ds with the SEC since 2020, most recently in Apr 2025 ($2.1 million sold to 9 investors).
Altis Biosystems investors
22 investors are on record for Altis Biosystems, including National Institutes of Health, Alexandria Venture Investments, Triangle Tweener Fund and Hatteras Venture Partners. The seed round in Mar 2025 drew 9 investors.
About Altis Biosystems
Developer of a stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research. The company's technology produces a layer of human or animal intestinal stem and differentiated cells either of the small or large intestines, enabling scientists to develop safe and more effective drugs using normal human intestinal tissue and reducing the need for animal testing.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2015
- Employees
- 27
- Website
- altisbiosystems.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.